Selected article for: "additional information and clinical disease"
Author: Pedersen, Niels C; Kim, Yunjeong; Liu, Hongwei; Galasiti Kankanamalage, Anushka C; Eckstrand, Chrissy; Groutas, William C; Bannasch, Michael; Meadows, Juliana M; Chang, Kyeong-Ok
Title: Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis
  • Document date: 2017_9_13
    • ID: y13gz4wz_8
    Snippet: Institutional rules precluded the use of cats obtained from shelters or similar facilities for research even of this type, thus requiring that all cats be legally owned/ adopted and treated with strict client consent (supplementary material). Cats with clinically apparent neurologic disease were also not included. Twenty cats from various regions of the USA, of varying age and with different presenting forms of FIP were ultimately enrolled in the.....
    Document: Institutional rules precluded the use of cats obtained from shelters or similar facilities for research even of this type, thus requiring that all cats be legally owned/ adopted and treated with strict client consent (supplementary material). Cats with clinically apparent neurologic disease were also not included. Twenty cats from various regions of the USA, of varying age and with different presenting forms of FIP were ultimately enrolled in the trial. This relatively small group of cats allowed valuable insights into trial design, owner interaction and compliance, monitoring safety and efficacy, establishing a minimal dosage regimen, evaluating disease relapses during or following treatment, and determining the clinical forms of FIP most amenable to treatment. This information will, hopefully, assist in the additional testing required for licensing and eventual commercialization of GC376 and for conducting similar trials of future antiviral drugs for FIPV and other chronic viral infections of cats.

    Search related documents:
    Co phrase search for related documents
    • additional testing and clinical form: 1
    • additional testing and efficacy safety: 1, 2, 3
    • antiviral drug and clinical form: 1, 2
    • antiviral drug and disease relapse: 1, 2
    • antiviral drug and efficacy safety: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • clinical form and efficacy safety: 1, 2, 3, 4, 5, 6
    • clinical form and FIP clinical form: 1, 2, 3
    • disease relapse and efficacy safety: 1, 2, 3, 4, 5